Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Jul;78(2):272–275. doi: 10.1038/bjc.1998.477

The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening of healthy post-menopausal women on tamoxifen or placebo.

T J Powles 1, T Bourne 1, S Athanasiou 1, J Chang 1, K Gruböck 1, S Ashley 1, L Oakes 1, A Tidy 1, J Davey 1, J Viggers 1, S Humphries 1, W Collins 1
PMCID: PMC2062882  PMID: 9683306

Abstract

Tamoxifen (tam) is used extensively for treatment of patients with breast cancer and is being evaluated for chemoprevention in healthy women. It has, however, been reported to increase the risk of endometrial cancer in post-menopausal women, probably by an oestrogenic effect on the endometrium. It also causes endometrial cysts and polyps. The aims of this study were to identify the incidence of endometrial thickening, polyps and cysts by transvaginal ultrasound (TVUS) screening of a population of post-menopausal healthy women in the Royal Marsden tamoxifen chemoprevention trial and to evaluate the possible benefit from the use of intermittent norethisterone (NE) in women with persistent changes. Since 1990, we have undertaken regular TVUS, using an endovaginal B mode probe, of the 463 post-menopausal women in the trial randomized to tam (20 mg day(-1)) or placebo (plac), without breaking the randomization code. Endometrial thickening (ET) was defined as > or = 8 mm at the widest point across the myometrial cavity in the longitudinal plane, including any stromal changes. Cystic changes were defined as more than one hypoechogenic area > 1 mm. Polyps were identified using saline hydrosonography. Oral NE (2.5 mg day(-1)) was used for 21 days out of 28 for three consecutive cycles by women with persistent endometrium > or = 8 mm, including cystic and polypoid changes. TVUS was repeated after the three courses to evaluate any change caused by NE and endometrial biopsies, including hysteroscopy, was performed on those women with persistent abnormalities. A persistent ET > or = 8 mm was identified in 56 (24%) of the 235 women on tamoxifen compared with only 5 (2%) of 228 women on placebo (P <0.0005). Stromal changes, including cysts, were detected in 36 (15%) and polyps in 26 (11%) of the women on tamoxifen compared with only two (< 1%) of the women on placebo (P << 0.0005). After 3 months of cyclical norethisterone, 39 of 47 women (83%) on tamoxifen had persistent ultrasound changes. However, 45 (96%) had a progesterone withdrawal bleed. Hysteroscopy was performed in 39 women on tamoxifen (28 endometrial biopsy, 15 polypectomy), five of whom had histological evidence of a proliferative endometrium and a further three had an atypical hyperplastic endometrium (one of whom had a focus of invasive carcinoma). The cysts and polyps which were detected in women on tam could not be reversed by NE and were presumably stromal and not of malignant risk. However, 96% of the women had withdrawal NE bleeding, indicating an oestrogenically primed endometrium which could be a mechanism for an increased risk of endometrial cancer. Further studies are required to ascertain whether a progestin would protect against this risk. As in other studies, these results indicate that any increased risk of endometrial cancer caused by tamoxifen is low, and that TVUS screening is probably not justified for asymptomatic women on tamoxifen.

Full text

PDF
272

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aleem F. A., Predanic M. Endometrial changes in patients on tamoxifen. Lancet. 1995 Nov 11;346(8985):1292–1293. [PubMed] [Google Scholar]
  2. Bourne T. H., Lawton F., Leather A., Granberg S., Campbell S., Collins W. P. Use of intracavity saline instillation and transvaginal ultrasonography to detect tamoxifen-associated endometrial polyps. Ultrasound Obstet Gynecol. 1994 Jan 1;4(1):73–75. doi: 10.1046/j.1469-0705.1994.04010073.x. [DOI] [PubMed] [Google Scholar]
  3. Carmichael P. L., Ugwumadu A. H., Neven P., Hewer A. J., Poon G. K., Phillips D. H. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res. 1996 Apr 1;56(7):1475–1479. [PubMed] [Google Scholar]
  4. Cohen I., Rosen D. J., Shapira J., Cordoba M., Gilboa S., Altaras M. M., Yigael D., Beyth Y. Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol. 1993 Jun;100(6):567–570. doi: 10.1111/j.1471-0528.1993.tb15310.x. [DOI] [PubMed] [Google Scholar]
  5. Cross S. S., Ismail S. M. Endometrial hyperplasia in an oophorectomized woman receiving tamoxifen therapy. Case report. Br J Obstet Gynaecol. 1990 Feb;97(2):190–192. doi: 10.1111/j.1471-0528.1990.tb01748.x. [DOI] [PubMed] [Google Scholar]
  6. De Muylder X., Neven P., De Somer M., Van Belle Y., Vanderick G., De Muylder E. Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynaecol Obstet. 1991 Oct;36(2):127–130. doi: 10.1016/0020-7292(91)90767-y. [DOI] [PubMed] [Google Scholar]
  7. Grady D., Gebretsadik T., Kerlikowske K., Ernster V., Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995 Feb;85(2):304–313. doi: 10.1016/0029-7844(94)00383-O. [DOI] [PubMed] [Google Scholar]
  8. Han X. L., Liehr J. G. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res. 1992 Mar 1;52(5):1360–1363. [PubMed] [Google Scholar]
  9. Ismail S. M. Pathology of endometrium treated with tamoxifen. J Clin Pathol. 1994 Sep;47(9):827–833. doi: 10.1136/jcp.47.9.827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lahti E., Blanco G., Kauppila A., Apaja-Sarkkinen M., Taskinen P. J., Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol. 1993 May;81(5 ):660–664. [PubMed] [Google Scholar]
  11. Martin E. A., Rich K. J., White I. N., Woods K. L., Powles T. J., Smith L. L. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis. 1995 Jul;16(7):1651–1654. doi: 10.1093/carcin/16.7.1651. [DOI] [PubMed] [Google Scholar]
  12. Neven P., De Muylder X., Van Belle Y., Vanderick G., De Muylder E. Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Gynecol Reprod Biol. 1990 May-Jun;35(2-3):235–238. doi: 10.1016/0028-2243(90)90167-y. [DOI] [PubMed] [Google Scholar]
  13. Neven P. Tamoxifen and endometrial lesions. Lancet. 1993 Aug 21;342(8869):452–452. doi: 10.1016/0140-6736(93)91590-i. [DOI] [PubMed] [Google Scholar]
  14. Phillips D. H., Potter G. A., Horton M. N., Hewer A., Crofton-Sleigh C., Jarman M., Venitt S. Reduced genotoxicity of [D5-ethyl]-tamoxifen implicates alpha-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis. 1994 Aug;15(8):1487–1492. doi: 10.1093/carcin/15.8.1487. [DOI] [PubMed] [Google Scholar]
  15. Powles T. J., Hardy J. R., Ashley S. E., Farrington G. M., Cosgrove D., Davey J. B., Dowsett M., McKinna J. A., Nash A. G., Sinnett H. D. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer. 1989 Jul;60(1):126–131. doi: 10.1038/bjc.1989.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Powles T. J., Hickish T. Tamoxifen therapy and carcinogenic risk. J Natl Cancer Inst. 1995 Sep 20;87(18):1343–1345. doi: 10.1093/jnci/87.18.1343. [DOI] [PubMed] [Google Scholar]
  17. Powles T. J., Jones A. L., Ashley S. E., O'Brien M. E., Tidy V. A., Treleavan J., Cosgrove D., Nash A. G., Sacks N., Baum M. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat. 1994;31(1):73–82. doi: 10.1007/BF00689678. [DOI] [PubMed] [Google Scholar]
  18. Powles T. J. The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet. 1992 Nov 7;340(8828):1145–1147. doi: 10.1016/0140-6736(92)93162-g. [DOI] [PubMed] [Google Scholar]
  19. Powles T. J., Tillyer C. R., Jones A. L., Ashley S. E., Treleaven J., Davey J. B., McKinna J. A. Prevention of breast cancer with tamoxifen--an update on the Royal Marsden Hospital pilot programme. Eur J Cancer. 1990;26(6):680–684. doi: 10.1016/0277-5379(90)90116-b. [DOI] [PubMed] [Google Scholar]
  20. Robinson S. P., Langan-Fahey S. M., Johnson D. A., Jordan V. C. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos. 1991 Jan-Feb;19(1):36–43. [PubMed] [Google Scholar]
  21. White I. N., de Matteis F., Davies A., Smith L. L., Crofton-Sleigh C., Venitt S., Hewer A., Phillips D. H. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis. 1992 Dec;13(12):2197–2203. doi: 10.1093/carcin/13.12.2197. [DOI] [PubMed] [Google Scholar]
  22. van Leeuwen F. E., Benraadt J., Coebergh J. W., Kiemeney L. A., Gimbrère C. H., Otter R., Schouten L. J., Damhuis R. A., Bontenbal M., Diepenhorst F. W. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994 Feb 19;343(8895):448–452. doi: 10.1016/s0140-6736(94)92692-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES